5-Chloro-3,3-dimethyl-N-isopropyl-1-(4-methoxybutyl)-2-oxo-N-[(3R)-piperidin-3-yl]indoline-6-carboxamide hydrochloride | 1163280-42-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 5-Chloro-3,3-dimethyl-N-isopropyl-1-(4-methoxybutyl)-2-oxo-N-[(3R)-piperidin-3-yl]indoline-6-carboxamide hydrochloride
• 英文别名: 5-Chloro-3,3-dimethyl-N-isopropyl-1-(4-methoxybutyl)-2-oxo-N-[(3R)-piperidin-3-yl] indoline-6-carboxamide hydrochloride；5-chloro-1-(4-methoxybutyl)-3,3-dimethyl-2-oxo-N-[(3R)-piperidin-3-yl]-N-propan-2-ylindole-6-carboxamide;hydrochloride
• CAS: 1163280-42-9
• 化学式: C₂₄H₃₆ClN₃O₃*ClH
• 分子量: 486.482
• InChiKey: PAASBGHEYYHWFL-UNTBIKODSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.42
• 重原子数：
  32
• 可旋转键数：
  8
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  61.9
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  tert-Butyl (3R)-3-[{[5-chloro-1-(4-methoxybutyl)-3,3-dimethyl-2-oxo-2,3-dihydro-1H-indol-6-yl]carbonyl}(isopropyl)amino]piperidine-1-carboxylate 在 盐酸 作用下， 以 1,4-二氧六环 为溶剂， 反应 2.0h， 生成 5-Chloro-3,3-dimethyl-N-isopropyl-1-(4-methoxybutyl)-2-oxo-N-[(3R)-piperidin-3-yl]indoline-6-carboxamide hydrochloride
  参考文献：
  名称：

  EP2243779

  摘要：

  公开号：

文献信息

• 6-Alkenyl-, 6-alkinyl- and 6-epoxy-epothilone derivatives, process for their production, and their use in pharmaceutical preparations
  申请人：Klar Ulrich

  公开号：US20050113429A1

  公开（公告）日：2005-05-26

  This invention describes the new 6-alkenyl- and 6-alkinyl-epothilone derivatives of general formula (I) in which R 1a , R 1b , R 2b , R 3a , R 3b , R 4 , R 5 , R 6 , R 7 , A, Y, D, E, G, Y and Z have the meanings that are indicated in the description. The new compounds interact with tubulin by stabilizing microtubuli that are formed. They are able to influence the cell-splitting in a phase-specific manner and thus find use in treating diseases or conditions associated with the need for cell growth, division and/or proliferation. Thus the compounds are suitable for treating malignant tumors, for example, ovarian, stomach, colon, adeno-, breast, lung, head and neck carcinomas, malignant melanoma, acute lymphocytic and myelocytic leukemia. In addition, they are suitable for anti-angiogenesis therapy as well as for treatment of chronic inflammatory diseases (such as psoriasis, arthritis). Methods of use and preparation of the compounds are also described.

  该发明描述了通式(I)中的新6-烯基-和6-炔基-epothilone衍生物，其中R1a、R1b、R2b、R3a、R3b、R4、R5、R6、R7、A、Y、D、E、G、Y和Z具有说明中指示的含义。这些新化合物通过稳定形成的微管蛋白质与微管结合。它们能够以特定阶段的方式影响细胞分裂，因此可用于治疗与细胞生长、分裂和/或增殖需求相关的疾病或状况。因此，这些化合物适用于治疗恶性肿瘤，例如卵巢、胃、结肠、腺癌、乳腺、肺、头颈癌、恶性黑色素瘤、急性淋巴细胞和骨髓性白血病。此外，它们也适用于抗血管生成治疗以及慢性炎症性疾病的治疗（如牛皮癣、关节炎）。还描述了这些化合物的使用方法和制备方法。
• BICYCLIC HETEROCYCLIC DERIVATIVE
  申请人：Nakahira Hiroyuki

  公开号：US20110190278A1

  公开（公告）日：2011-08-04

  The present invention relates to a compound of the following formula (I) or a pharmaceutically acceptable salt thereof, being useful as a renin inhibitor. [wherein R 1a is halogen, etc.; R 1m is H, etc.; G 1 is —N(R 1b )—, etc.; G 2 is —CO—, etc.; G 3 is —C(R 1c )(R 1d )—, etc.; G 4 is oxygen, etc.; R 1b is optionally substituted C 1-6 alkyl, etc.; R 1c and R 1d are independently the same or different, H, etc.; R 3 is H, optionally substituted C 1-6 alkyl, etc.; R 3a , R 3b , R 3 c and R 3d are independently the same or different, and a group: -A-B (said A is single bond, etc., and said B is H, etc.), etc.; and n is 1, etc.]

  本发明涉及以下式（I）的化合物或其药学上可接受的盐，其可用作肾素抑制剂。[其中，R1a是卤素等；R1m是H等；G1是—N（R1b）—等；G2是—CO—等；G3是—C（R1c）（R1d）—等；G4是氧等；R1b是可选取代的C1-6烷基等；R1c和R1d独立选择为H等；R3是H、可选取代的C1-6烷基等；R3a、R3b、R3c和R3d独立选择为相同或不同的基团：-A-B（其中A是单键等，B是H等）等；n为1等。]
• Bicyclic heterocyclic derivative
  申请人：Nakahira Hiroyuki

  公开号：US08389511B2

  公开（公告）日：2013-03-05

  The present invention relates to a compound of the following formula (I) or a pharmaceutically acceptable salt thereof, being useful as a renin inhibitor. [wherein R1a is halogen, etc.; R1m is H, etc.; G1 is —N(R1b)—, etc.; G2 is —CO—, etc.; G3 is —C(R1c)(R1d)—, etc.; G4 is oxygen, etc.; R1b is optionally substituted C1-6 alkyl, etc.; R1c and R1d are independently the same or different, H, etc.; R3 is H, optionally substituted C1-6 alkyl, etc.; R3a, R3b, R3c and R3d are independently the same or different, and a group: -A-B (said A is single bond, etc., and said B is H, etc.), etc.; and n is 1, etc.]

  本发明涉及以下式（I）的化合物或其药学上可接受的盐，其作为肾素抑制剂有用。[其中R1a为卤素等；R1m为H等；G1为—N（R1b）—等；G2为—CO—等；G3为—C（R1c）（R1d）—等；G4为氧等；R1b为可选取代的C1-6烷基等；R1c和R1d独立且相同或不同，为H等；R3为H、可选取代的C1-6烷基等；R3a、R3b、R3c和R3d独立且相同或不同，为-A-B基团（其中A为单键等，B为H等）等；n为1等。]
• 6-ALKENYL-, 6-ALKINYL- AND 6-EPOXY-EPOTHILONE DERIVATIVES, PROCESS FOR THEIR PRODUCTION, AND THEIR USE IN PHARMACEUTICAL PREPARATIONS
  申请人：Klar Ulrich

  公开号：US20100168179A1

  公开（公告）日：2010-07-01

  This invention describes the new 6-alkenyl- and 6-alkinyl-epothilone derivatives of general formula (I) in which R 1a , R 1b , R 2a , R 3a , R 3b , R 4 , R 5 , R 6 , R 7 , A, Y, D, E, G, Y and Z have the meanings that are indicated in the description. The new compounds interact with tubulin by stabilizing microtubuli that are formed. They are able to influence the cell-splitting in a phase-specific manner and thus find use in treating diseases or conditions associated with the need for cell growth, division and/or proliferation. Thus the compounds are suitable for treating malignant tumors, for example, ovarian, stomach, colon, adeno-, breast, lung, head and neck carcinomas, malignant melanoma, acute lymphocytic and myelocytic leukemia. In addition, they are suitable for anti-angiogenesis therapy as well as for treatment of chronic inflammatory diseases (such as psoriasis, arthritis). Methods of use and preparation of the compounds are also described.
• US7125893B1
  申请人：——

  公开号：US7125893B1

  公开（公告）日：2006-10-24